Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials

References

• BladéJSamsonDReeceDCriteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantationBr J Haematol19981025111511239753033
   PubMed Web of Science ®Google Scholar
• BeckerNEpidemiology of multiple myelomaRecent Results Cancer Res20111831253521509679
   PubMedGoogle Scholar
• SinghalSMehtaJDesikanRAntitumor activity of thalidomide in refractory multiple myelomaN Engl J Med1999341211565157110564685
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med2003348262609261712826635
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWAssessment of Proteasome Inhibition for Extending Remissions (APEX) InvestigatorsBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• RajkumarSVHaymanSRLacyMQCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood2005106134050405316118317
   PubMed Web of Science ®Google Scholar
• RichardsonPGBloodEMitsiadesCSA randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood2006108103458346416840727
   PubMed Web of Science ®Google Scholar
• BrennerHGondosAPulteDRecent major improvement in long-term survival of younger patients with multiple myelomaBlood200811152521252617901246
   PubMed Web of Science ®Google Scholar
• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood200811152516252017975015
   PubMed Web of Science ®Google Scholar
• EngelhardtMTerposEKleberMEuropean Myeloma NetworkEuropean Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaHaematologica201499223224224497560
   PubMed Web of Science ®Google Scholar
• CavoMRajkumarSVPalumboAInternational Myeloma Working GroupInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood2011117236063607321447828
   PubMed Web of Science ®Google Scholar
• CavoMTacchettiPPatriarcaFBortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyLancet201037697582075208521146205
   PubMed Web of Science ®Google Scholar
• MorganGJDaviesFEGregoryWMNational Cancer Research Institute Haematological Oncology Clinical Studies GroupCyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsHaematologica201197344245022058209
   PubMed Web of Science ®Google Scholar
• LokhorstHMvan der HoltBZweegmanSDutch-Belgian Hemato-Oncology Group (HOVON)A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myelomaBlood201011561113112019880501
   PubMed Web of Science ®Google Scholar
• LumleyTNetwork meta-analysis for indirect treatment comparisonsStat Med200221162313232412210616
   PubMed Web of Science ®Google Scholar
• van ValkenhoefGLuGde BrockBHillegeHAdesAEWeltonNJAutomating network meta-analysisRes Synth Methods20123428529926053422
   PubMed Web of Science ®Google Scholar
• HuttonBSalantiGCaldwellDMThe PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanationsAnn Intern Med20151621177778426030634
   PubMed Web of Science ®Google Scholar
• DurieBGHarousseauJLMiguelJSInternational Myeloma Working GroupInternational uniform response criteria for multiple myelomaLeukemia20062091467147316855634
   PubMed Web of Science ®Google Scholar
• TierneyJFStewartLAGhersiDPractical methods for incorporating summary time-to-event data into meta-analysisTrials2007811617555582
   PubMed Web of Science ®Google Scholar
• GuyotPAdesAEOuwensMJWeltonNJEnhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Med Res Methodol201212922297116
   PubMed Web of Science ®Google Scholar
• LudwigHGreilRMassziTBortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with newly diagnosed multiple myeloma: 5-year follow-upBr J Haematol2015171334435426153365
   PubMed Web of Science ®Google Scholar
• RajkumarSVBloodEVesoleDFonsecaRGreippPREastern Cooperative Oncology GroupPhase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology GroupJ Clin Oncol200624343143616365178
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJMeasuring inconsistency in meta-analysesBr Med J2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• SonneveldPSchmidt-WolfIGvan der HoltBBortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trialJ Clin Oncol201230242946295522802322
   PubMed Web of Science ®Google Scholar
• MoreauPAvet-LoiseauHFaconTBortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaBlood2011118225752575821849487
   PubMed Web of Science ®Google Scholar
• RosiñolLOriolATeruelAIPrograma para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) groupSuperiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM studyBlood201212081589159622791289
   PubMed Web of Science ®Google Scholar
• MoreauPHulinCMacroMVTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialBlood2016127212569257427002117
   PubMed Web of Science ®Google Scholar
• CavoMZamagniETosiPBologna 2002 StudySuperiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood20051061353915761019
   PubMed Web of Science ®Google Scholar
• HarousseauJLAttalMAvetloiseauHBortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trialJ Clin Oncol201028304621462920823406
   PubMed Web of Science ®Google Scholar
• MaiEKBertschUDürigJPhase III trial of bortezomib, cyclophosphamide, dexamethasone (VCD) versus bortezomib, doxorubicin, dexamethasone (PAd) in newly-diagnosed myelomaLeukemia20152981721172925787915
   PubMed Web of Science ®Google Scholar
• MellqvistUHLenhoffSJohnsenHECyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasoneCancer2008112112913517973267
   PubMed Web of Science ®Google Scholar
• KumarSFlinnIRichardsonPGRandomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myelomaBlood2012119194375438222422823
   PubMed Web of Science ®Google Scholar
• KumarLMookerjeeASharmaALow dose dexamethasone plus lenalidomide (Len-dexa) versus thalidomide (Thal-dexa) as induction therapy for newly diagnosed multiple myeloma: a phase III, randomized studyClin Lymphoma Myeloma Leuk201515e146e146
   Google Scholar
• MoreauPAttalMFaconTFrontline therapy of multiple myelomaBlood2015125203076308425838345
   PubMed Web of Science ®Google Scholar
• NookaAKKaufmanJLBeheraMBortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trialsCancer2013119234119412824005889
   PubMed Web of Science ®Google Scholar
• SonneveldPGoldschmidtHRosiñolLBortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: a meta-analysis of phase III randomized, controlled trialsJ Clin Oncol201331263279328723897961
   PubMed Web of Science ®Google Scholar
• HuangHZhouLPengLFuWZhangCHouJBortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trialsLeuk Res20143891048105425052306
   PubMed Web of Science ®Google Scholar
• RosiñolLKumarSMoreauPCavoMInitial treatment of transplant- eligible patients in multiple myelomaExpert Rev Hematol201471435324392968
   PubMed Web of Science ®Google Scholar